Differential Expression of WT1 and p53 in Serous and Endometrioid Carcinomas of the Endometrium

Jennifer A. Egan, Marina C. Ionescu, Elizabeth Eapen, Joan G. Jones, David S. Marshall

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Wilms' tumor antibody (WT1) has recently been reported to be reactive in most ovarian and peritoneal serous carcinomas, but few studies have looked at WT1 reactivity in endometrial carcinomas. p53, like WT1, is a tumor suppressor gene and in its mutated form is frequently present in endometrial serous carcinoma. Routine immunohistochemical staining for p53 and WT1 was performed in 70 endometrial carcinomas (39 endometrioid and 31 serous) of varying differentiation using tissue microarrays. Only 2 (7.5%) serous carcinomas and none of the endometrioid carcinomas (0%) were reactive for WT1. p53 immunoreactivity was found in 26 (83.9%) serous carcinomas and in 2 (5.1%) endometrioid carcinomas. We conclude that WT1 and p53 expression are not related and that WT1 expression in endometrial serous carcinoma differs from that of its extrauterine counterparts.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalInternational Journal of Gynecological Pathology
Issue number2
StatePublished - Apr 2004


  • Endometrioid carcinoma
  • Endometrium
  • P53
  • Serous carcinoma
  • Uterus
  • WT1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Differential Expression of WT1 and p53 in Serous and Endometrioid Carcinomas of the Endometrium'. Together they form a unique fingerprint.

Cite this